Thursday, November 12, 2026

USD/EUR Bearish Momentum: 0.763% Down In The Last 24 Hours

USD/EUR Bearish Momentum: 0.763% Down In The Last 24 Hours

(VIANEWS) - USD/EUR (USDEUR) has been up by 0.7628% for the last session's close. At 09:15 EST on Wednesday, 12 June, USD/EUR (USDEUR) is $0.92.

USD/EUR (USDEUR) Range

Concerning USD/EUR's daily highs and lows, it's 0.752% down from its trailing 24 hours low of $0.93 and 0.774% down from its trailing 24 hours high of $0.93.

USD/EUR's yearly highs and lows, it's 4.138% up from its 52-week low and 3.49% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • According to FXStreet on Wednesday, 12 June, "The USD/JPY pair strengthens as investors favor the US Dollar (USD) ahead of the Federal Reserve's (Fed) decision and the release of US inflation figures for May, scheduled for later in the North American trading hours.", "A breach below this level might intensify downward pressure on the USD/JPY pair, potentially directing it toward the throwback support area around 152.80."
  • Usd/jpy sticks to modest intraday gains above 157.00 mark, over one-week high. According to FXStreet on Tuesday, 11 June, "This, in turn, favors the USD bulls and supports prospects for an extension of the USD/JPY pair's recent rise from the 50-day Simple Moving Average (SMA).", "This, along with a stable performance around the equity markets, is seen undermining the Japanese Yen (JPY) and turning out to be a key factor acting as a tailwind for the USD/JPY pair."
  • According to FXStreet on Monday, 10 June, "A breakthrough above this level could exert support to lead the USD/JPY pair to navigate the area around the upper boundary nearing the level of 158.60. ", "A break below this level could increase pressure on the USD/JPY pair, potentially leading it toward the throwback support region around 152.80."
  • Usd/jpy price analysis: struggles at 157.00, drops and remains subdued. According to FXStreet on Tuesday, 11 June, "Conversely, if USD/JPY buyers lift the exchange rate past the 157.00 figure, the next resistance would be the May 29 high of 157.71. ", "The USD/JPY retreats during the North American session yet is virtually unchanged as traders brace for Wednesday's busy economic docket, which will feature May's US Consumer Price Index (CPI) data and the Federal Open Market Committee (FOMC) monetary policy decision. "
  • According to FXStreet on Tuesday, 11 June, "A breakthrough above this level could provide support, potentially guiding the USD/JPY pair toward the vicinity of the upper boundary near the level of 158.60. ", "The USD/JPY pair received support from a stronger US Dollar (USD) as investors remained cautious ahead of the Federal Reserve's (Fed) decision, along with the US inflation figures for May on Wednesday."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com